Gemcitabine Combined With Endostar and Envafolimab in Elderly Patients With Locally Advanced Nasopharyngeal Carcinoma

Phase 2RecruitingNCT06055816

Zhejiang Cancer Hospital40 enrolled

Overview

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Nasopharyngeal Carcinoma

Interventions

Endostar and EnvafolimabDRUG

Neoadjuvant therapy consisting of gemcitabine (1000mg/m2 d1,8) , endostar (150mg 3-day continuous infusion) and envafolimab (240mg d1) was given every 3 weeks for 3 cycles. Endostar, administered every 3 weeks (150mg 3-day continuous infusion), was given concurrently with intensity-modulated radiotherapy.

Eligibility

Sex: ALLMin age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Aged ≥65 years with newly pathologically confirmed NPC * Karnofsky performance status ≥60 * Clinical stage III-IVA (Union for International Cancer Control and American Joint Committee on Cancer staging system for NPC, 8th edition) * Adequate organ function Exclusion Criteria: * Cancer history * Prior radiotherapy, cytotoxic chemotherapy, immunotherapy or target therapy * Life-expectance within 6 months

Locations (1)

Zhejiang Cancer Hospital

Hangzhou, Zhejiang, China

RECRUITING

Outcomes

Primary Outcomes

The proportion of patients with grade 3 or higher adverse events (AEs).

The primary endpoint was the safety profile. AEs were scored according to the Common Terminology Criteria for Adverse Events (CTCAE) v5.0

Time frame: Up to 24 weeks

Central Contacts

Xiaozhong Chen

CONTACT

88128202 chenxz@zjcc.org.cn

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.